Related Experiment Video
Updated: Jul 5, 2026

Inducing Apical Periodontitis in Mice
Published on: August 6, 2019
Sidt2 Knockdown Aggravates Apical Periodontitis Via Autocrine Tumour Necrosis Factor-Alpha
Biao Li1, Gengming Zhang2, Mingyuan Du2
1State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School and Hospital of Stomatology, Wuhan University, Wuhan, China.
SID1 transmembrane family member 2 (Sidt2) suppresses inflammation and bone loss in apical periodontitis by inhibiting tumour necrosis factor-alpha (TNF-α) signaling. Sidt2 is a potential therapeutic target for bone resorption diseases.
Area of Science:
- Biomedical Science
- Immunology
- Oral Biology
Background:
- Apical periodontitis (AP) involves inflammation and bone loss, with high tumour necrosis factor-alpha (TNF-α) expression.
- SID1 transmembrane family member 2 (Sidt2), a lysosomal protein, is implicated in inflammation, but its role in AP is unknown.
Purpose of the Study:
- To investigate the effect of Sidt2 on apical periodontitis (AP) and its underlying mechanisms.
- To explore Sidt2's role in inflammation and osteoclast differentiation in AP.
Main Methods:
- An AP mouse model was created, with Sidt2 expression inhibited using adenovirus-associated virus.
- Micro-computed tomography, histological staining, and molecular analyses (qPCR, Western blot, ELISA, RNA sequencing) were performed.
- Osteoclast differentiation and TNF-α signaling were assessed in vivo and in vitro (RAW 264.7 cells).
Main Results:
- Sidt2 expression was suppressed, while TNF-α increased in AP models.
- Sidt2 inhibition exacerbated inflammation and bone loss in AP, upregulating osteoclast differentiation.
- Sidt2 knockdown enhanced TNF-α production; neutralizing TNF-α partially reversed Sidt2 inhibition-induced osteoclast differentiation.
Conclusions:
- Sidt2 negatively regulates autocrine TNF-α signaling, impacting osteoclast differentiation in AP.
- Sidt2 represents a potential therapeutic target for managing bone resorption in AP.
Related Concept Videos
TGF - β Signaling Pathway
Acute Pancreatitis II: Pathophysiology
Inflammatory Bowel Disease II: Ulcerative Colitis